A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

NCT02207725 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Bleeding

Interventions

BIOLOGICAL: Andexanet
OTHER: Placebo

Sponsor

Portola Pharmaceuticals